Group 1 - The company announced a cash dividend distribution plan for the first half of 2025, proposing a distribution of 1.00 yuan (including tax) for every 10 shares held by shareholders [2] - The total share capital used for the dividend calculation is 105,907,460 shares, after excluding 373,500 shares held in the repurchase account [2] - The record date for the dividend is set for September 15, 2025, and the ex-dividend date is September 16, 2025 [2]

证券代码：002864 证券简称：盘龙药业 公告编号：2025-040 陕西盘龙药业集团股份有限公司 关于召开 2025 年第二次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司于 2025 年 8 月 28 日在巨潮资讯网上披露了《关于 召开 2025 年第二次临时股东会的通知》（公告编号：2025-035），现发布本次股东会 的提示性公告如下： 一、召开会议的基本情况 1.股东会届次：2025 年第二次临时股东会； 6.会议的股权登记日：2025 年 9 月 5 日； 7.出席对象： 1 （1）在股权登记日持有公司股份的普通股股东或其代理人； 2.股东会的召集人：陕西盘龙药业集团股份有限公司（以下简称"公司"）董事会； 3.会议召开的合法、合规性：经公司第四届董事会第二十五次会议审议通过，决定 召开公司 2025 年第二次临时股东会，本次会议的召开符合《中华人民共和国公司法》 《上市公司股东会规则》《深圳证券交易所股票上市规则》等有关法律法规及《公司章 程》的规定。 4.会议召开的日期、时间： （1）现场 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-039 陕西盘龙药业集团股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本次除权除息前公司总股本为 106,280,960 股，按总股本折算的每 10 股现金 分红(含税)=( 现金分红总额/总股本)*10=(10,590,746.00 元/106,280,960 股)*10=0.996485 元(保留到小数点后六位，最后一位直接截取，不四舍五入)。 特别提示： 1.陕西盘龙药业集团股份有限公司（以下简称"公司"）回购专用账户持有 的股份 373,500 股不参与本次权益分派。 2.公司 2025 年半年度权益分派方案为：以公司现有总股本 106,280,960 股剔 除回购专用账户中已回购股份 373,500 股后的股本 105,907,460 股为基数，向全 体股东每 10 股派发现金分红 1.00 元（含税）。公司本次实际派发的现金分红总 额 = 实 际 参 与 分 配 的 总 股 本 * 分 配 比 例 ， 即 105,907,460 股 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002864 证券简称：盘龙药业 公告编号：2025-038 一、业绩发布会的安排 1、召开时间：2025年9月10日（星期三）下午15:00-17:00 2、召开方式：同花顺路演平台采用网络远程平台文字互动方式 3、出席人员：董事长谢晓林先生，董事会秘书吴杰先生，独立董事任海云女士，独立董事牛晓峰先 生，副总裁、研究院院长张德柱先生，财务总监祝凤鸣先生。 二、投资者参与方式 问题征集方式：https://board.10jqka.com.cn/fe/roadshow/questionCollection.html?id=1010629 陕西盘龙药业集团股份有限公司 关于举行2025年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假 记载、误导性陈述或重大 遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于2025年8月28日在巨潮资讯网 （www.cninfo.com.cn）上披露了《2025 年半年度报告》。为使广大投资者更加全面、深入地了解公司 经营情况，公司将于2025年9月10日召开2 ...

Group 1 - The company, Panlong Pharmaceutical, announced that it will hold an online performance briefing for the first half of 2025 on September 10, 2025, from 15:00 to 17:00 [2]

陕西盘龙药业集团股份有限公司（以下简称"公司"）于2025年8月28日在 巨潮资讯网（www.cninfo.com.cn）上披露了《2025 年半年度报告》。为使广大 投资者更加全面、深入地了解公司经营情况，公司将于2025年9月10日召开2025年 半年度业绩说明会，就投资者关心的问题进行交流。 一、业绩发布会的安排 1、召开时间：2025年9月10日（星期三）下午15:00-17:00 2、召开方式：同花顺路演平台采用网络远程平台文字互动方式 证券代码：002864 证券简称：盘龙药业 公告编号：2025-038 陕西盘龙药业集团股份有限公司 关于举行2025年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假 记载、误导性陈述或重大遗漏。 3、出席人员：董事长谢晓林先生，董事会秘书吴杰先生，独立董事任海云女士， 独立董事牛晓峰先生，副总裁、研究院院长张德柱先生，财务总监祝凤鸣先生。 二、投资者参与方式 欢迎广大投资者积极参与！ 陕西盘龙药业集团股份有限公司董事会 2025年9月5日 https://board.10jqka.com.cn/fe/roadsho ...

Group 1: Company Performance - The company's traditional Chinese medicine business showed steady growth in the first half of 2025, driven by core products and deepened sales strategies [2][3] - "Panlong Seven Tablets," a core product, maintained a leading market position with a market share of 7.73% in the traditional Chinese medicine market for musculoskeletal diseases [6] - The revenue from the Chinese herbal pieces business increased by 380.89% year-on-year, contributing approximately 123 million yuan to the overall revenue [7] Group 2: Product Strategy - The company aims to cultivate and expand secondary products alongside "Panlong Seven Tablets," leveraging a diverse product portfolio including "Bone Health Tablets" and "Gout Relief Tablets" [3] - The company employs targeted marketing strategies for secondary and tertiary products to complement core products and support steady growth in traditional Chinese medicine [3] Group 3: Financial Health - The company reported a solid financial status with ample cash flow, providing a strong foundation for strategic development [4] - The increase in accounts receivable in the first half of 2025 was primarily due to the significant growth in the Chinese herbal pieces business [7] Group 4: Research and Development - The company is committed to increasing R&D investments, focusing on new drug development and innovative drugs with good market prospects [4] - The company has completed the construction of an intelligent production line for Chinese herbal formula granules, with 310 products registered and listed in 18 provinces [7][8] Group 5: Competitive Advantages - "Panlong Seven Tablets" is recognized for its unique formulation and clinical efficacy, supported by nearly 180 academic papers published in authoritative journals [5] - The product has been included in multiple national clinical guidelines and is recognized as a recommended medication for various musculoskeletal conditions [5] Group 6: Future Outlook - The company plans to explore new business opportunities cautiously, focusing on vertical integration and potential acquisitions in the musculoskeletal disease sector [4] - The company emphasizes enhancing shareholder returns through increased dividend frequency and amounts, with a three-year dividend plan approved [8]

Investment Rating - The investment rating for the company is "Buy" with a target of outperforming the industry index by more than 15% over the next six months [5][17]. Core Insights - The company has shown steady revenue growth, with a projected increase in revenue from 9.81 billion CNY in 2023 to 16.71 billion CNY by 2027, reflecting a compound annual growth rate (CAGR) of approximately 14.5% [1][4]. - The net profit attributable to the parent company is expected to grow from 1.10 billion CNY in 2023 to 1.69 billion CNY in 2027, with a notable increase in growth rates, particularly 18.0% in 2027 [1][4]. - The company's leading product, Panlong Qipian, has seen an increase in market share, reaching 7.73% in 2024, maintaining its position as a top competitor in the market for traditional Chinese medicine targeting musculoskeletal diseases [2]. Financial Performance - In the first half of 2025, the company achieved revenue of 574 million CNY, a year-on-year increase of 26.06%, and a net profit of 60 million CNY, up 0.81% year-on-year [1][3]. - The traditional Chinese medicine segment has shown exceptional performance, with revenue growth of 380.89% in the same period [3]. - The company has successfully reduced its expense ratios, with a sales expense ratio of 31.55%, down 8.46 percentage points year-on-year, and a management expense ratio of 5.30%, down 1.57 percentage points year-on-year [3]. Product Development and Market Strategy - The company is accelerating its innovative drug development, with several products in various stages of clinical trials, including PL-JT004 entering the CDE clinical acceptance phase [2]. - The marketing network has been strengthened, covering over 5,000 grade A medical institutions and penetrating more than 30,000 retail pharmacies, creating a dual-driven sales model [3]. - The company aims to build a comprehensive product ecosystem that includes both oral and external applications, as well as classic formulations and high-end innovative drugs [2].

Group 1 - The core viewpoint of the article highlights the recognition of outstanding corporate secretaries, specifically the awarding of the 11th Golden Unicorn Best Corporate Secretary Award to Wu Jie from Panlong Pharmaceutical for his exceptional professional capabilities and performance [1][2] - The role of corporate secretaries is emphasized as a crucial link between listed companies and the capital market, serving multiple functions such as governance, strategic advisory, information disclosure, and investor relations [1][2] - The Golden Unicorn Best Corporate Secretary selection has been held for eleven years, recognizing over 900 outstanding corporate secretaries, and is regarded as a highly authoritative award in the industry, focusing on information disclosure quality, investor communication effectiveness, and contributions to corporate governance and ESG [1][2] Group 2 - An excellent corporate secretary is characterized by their ability to effectively communicate company value in complex market environments, innovate communication methods while adhering to compliance, and demonstrate corporate responsibility during critical moments [2] - Wu Jie, the recipient of the award, exemplifies the qualities of an outstanding corporate secretary, reflecting both personal excellence in capital communication and governance, as well as market and investor recognition of Panlong Pharmaceutical's governance and value growth [2]

Core Viewpoint - Panlong Pharmaceutical (002864.SZ) reported a strong performance for the first half of 2025, achieving revenue growth and profit increase, driven by its "one body, two wings, three depths" strategy, with significant contributions from its core product, Panlong Seven Tablets, and a remarkable growth in traditional Chinese medicine (TCM) decoction pieces [3][4][5]. Financial Performance - In the first half of 2025, Panlong Pharmaceutical achieved revenue of 574 million yuan, a year-on-year increase of 26.06%, and a net profit attributable to shareholders of 60.14 million yuan, up 0.81% [4]. - The company’s self-produced TCM contributed 319 million yuan in revenue, a growth of 2.29%, accounting for 55.5% of total revenue, with a gross margin of 87.26% [5]. - The TCM decoction pieces saw a staggering revenue increase of 380.89%, reaching 123 million yuan, marking it as the fastest-growing product in the first half of the year [5]. Product and Market Strategy - Panlong Seven Tablets maintained a strong market position with a market share of 7.73% in the TCM market for musculoskeletal diseases [7]. - The company has transformed its marketing system, covering over 5,000 medical institutions and tens of thousands of retail terminals, establishing a dual-driven model of "medical + retail" [5][6]. - The company is embracing the "Internet + medicine" trend, enhancing brand communication through digital platforms, which has significantly increased product search volume [8]. Research and Development - R&D investment reached 15.85 million yuan in the first half of 2025, an increase of 11.18%, focusing on innovative TCM and chemical generic drugs [9]. - The number of registered TCM formula granules increased to 310, indicating a robust pipeline for future growth [9][10]. - The company has established a strong R&D platform, with 79 patents held, including 36 authorized invention patents [10]. Investment and Growth Strategy - Panlong Pharmaceutical is actively engaging in investment activities to support its product development goals, with significant progress in its industrial fund investments [11][12]. - The company is focusing on integrating its core business with investment projects to enhance resource synergy and efficiency [12][13]. - A new TCM innovation drug R&D platform has been established in the Guangdong-Hong Kong-Macao Greater Bay Area, targeting the development of TCM for chronic orthopedic diseases [13].